Devyser wins tender in Italy worth approximately SEK 5.7 million – doubling test volumes compared with previous agreement
Devyser Diagnostics AB, through its Italian subsidiary, has been awarded a renewed tender by...
Hereditary cancer | September 30, 2022
Check out a recent publication from Capone et al from the University of Florence!
In this study, the Devyser BRCA test was used to analyze 227 patient DNA samples. They concluded that 100% of the expected SNVS and CNVS were detected and that the single-tube PCR-based library preparation format of the kit offers a decrease in processing time as well as a reduced risk of cross-contamination.
Devyser Diagnostics AB, through its Italian subsidiary, has been awarded a renewed tender by...
Read More
Devyser announced that One Lambda™ Devyser Accept cfDNA, its test for monitoring kidney transplant...
Read More
Devyser, a global leader in advanced molecular diagnostics, today announced the first commercial...
Read More
One Lambda™ Devyser Chimerism Plus is a next generation solution for chimerism analysis following...
Read More